After passing through rough waters, Alexion Pharmaceuticals Inc. sought to reassure investors on its 2016 performance, touting total revenues of $3.084 billion, an 18 percent year-over-year increase, and 2016 net sales of $2.843 billion for Soliris (eculizumab) compared to $2.591 billion in 2015, or an increase of nearly 10 percent.